secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000950170-25-102394
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum reports Q2 net loss $6.5M; ORLYNVAH launch on track for August 2025
--------------------------------------------------------------------------

- Net loss $6.5M (non-GAAP $5.1M) vs $5.0M prior year; cash $13.0M at June 30, 2025.
- ORLYNVAH™ launch expected by end of August 2025 for uUTIs; first oral penem approved in U.S.
- Entered commercialization agreement with EVERSANA; hired Christine Coyne as CCO.
- Pfizer extended $20M milestone payment deferral to October 2029.
- Canadian patent issued covering sulopenem/probenecid combination, expiring 2039.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025102394/0000950170-25-102394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025102394/itrm-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-102394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer